Información de Regeneron Pharmaceuticals Inc, dividendo de Regeneron Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de Regeneron Pharmaceuticals Inc Compañía

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Información de Regeneron Pharmaceuticals Inc



Símbolo de cotizaciónREGN

Nombre de la empresaRegeneron Pharmaceuticals Inc

Fecha de salida a bolsaApr 02, 1991

Director ejecutivoSchleifer (Leonard S)

Número de empleados15106

Tipo de seguridadOrdinary Share

Fin del año fiscalApr 02

Dirección777 Old Saw Mill River Road

CiudadTARRYTOWN

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal10591

Teléfono17813705000

Sitio Webhttps://www.regeneron.com/

Símbolo de cotizaciónREGN

Fecha de salida a bolsaApr 02, 1991

Director ejecutivoSchleifer (Leonard S)

Ejecutivos de Regeneron Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.13M

+14941.00%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

688.05K

+17578.00%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

52.18K

-2213.00%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+1080.00%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.17K

-743.00%

Mr. George L. Sing

Independent Director

33.06K

+155.00%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

21.78K

+2035.00%

Mr. Arthur F. (Art) Ryan

Independent Director

17.81K

+155.00%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.49K

+119.00%

Dr. Michael S. Brown, M.D.

Independent Director

12.77K

+155.00%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.13M

+14941.00%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

688.05K

+17578.00%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

52.18K

-2213.00%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+1080.00%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.17K

-743.00%

Mr. George L. Sing

Independent Director

33.06K

+155.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Sanofi

1.62B

43.07%

EYLEA

680.60M

18.13%

EYLEA HD

430.60M

11.47%

Bayer

344.80M

9.18%

Libtayo

219.10M

5.84%

Otro

462.20M

12.31%

La empresa aún no ha revelado los datos relevantes.

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Sanofi

1.62B

43.07%

EYLEA

680.60M

18.13%

EYLEA HD

430.60M

11.47%

Bayer

344.80M

9.18%

Libtayo

219.10M

5.84%

Otro

462.20M

12.31%

Estadísticas de accionistas

Actualizado: dom., 16 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

8.73%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

Otro

74.18%

Accionistas

Proporción

The Vanguard Group, Inc.

8.73%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

Otro

74.18%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

45.29%

Investment Advisor/Hedge Fund

31.13%

Hedge Fund

5.04%

Pension Fund

2.77%

Research Firm

2.72%

Bank and Trust

2.20%

Individual Investor

2.07%

Sovereign Wealth Fund

1.23%

Insurance Company

0.20%

Otro

7.36%

Participación institucional



Actualizado: jue., 1 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

2674

93.48M

90.51%

-2.18M

2025Q3

2596

94.26M

91.26%

-4.21M

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

9.00M

8.71%

-376.36K

-4.02%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

5.46M

5.29%

-204.21K

-3.60%

Sep 30, 2025

State Street Investment Management (US)

4.69M

4.54%

-140.78K

-2.91%

Sep 30, 2025

Dodge & Cox

4.55M

4.41%

+724.56K

+18.94%

Sep 30, 2025

JP Morgan Asset Management

2.95M

2.85%

+130.73K

+4.64%

Sep 30, 2025

Geode Capital Management, L.L.C.

2.54M

2.46%

+70.84K

+2.87%

Sep 30, 2025

Invesco Capital Management (QQQ Trust)

2.32M

2.24%

+133.61K

+6.12%

Dec 31, 2025

Putnam Investment Management, L.L.C.

2.15M

2.08%

+117.43K

+5.78%

Sep 30, 2025

Capital World Investors

2.00M

1.93%

+32.35K

+1.65%

Sep 30, 2025

Loomis, Sayles & Company, L.P.

1.98M

1.92%

+38.38K

+1.98%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

ProShares Ultra Nasdaq Biotechnology

6.6%

Invesco Nasdaq Biotechnology ETF

6.55%

Amplify Weight Loss Drug & Treatment ETF

6.4%

iShares Biotechnology ETF

5.9%

Simplify Health Care ETF

5.54%

VanEck Biotech ETF

5.51%

Invesco Biotechnology & Genome ETF

5.4%

iShares Genomics Immunology and Healthcare ETF

4.97%

First Trust NASDAQ Pharmaceuticals ETF

4.36%

First Trust NYSE Arca Biotechnology Index Fund

3.88%

ProShares Ultra Nasdaq Biotechnology

Proporción6.6%

Invesco Nasdaq Biotechnology ETF

Proporción6.55%

Amplify Weight Loss Drug & Treatment ETF

Proporción6.4%

iShares Biotechnology ETF

Proporción5.9%

Simplify Health Care ETF

Proporción5.54%

VanEck Biotech ETF

Proporción5.51%

Invesco Biotechnology & Genome ETF

Proporción5.4%

iShares Genomics Immunology and Healthcare ETF

Proporción4.97%

First Trust NASDAQ Pharmaceuticals ETF

Proporción4.36%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.88%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Jan 30, 2026

REGN.NB Interim Cash Dividend of gross USD 0.94 paid on Mar 05, 2026 going ex on Feb 20, 2026

Feb 20, 2026

Mar 05, 2026

Feb 20, 2026

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos